Cited 13 times in
Inhibition of choroidal neovascularisation in mice by systemic administration of the multikinase inhibitor, sorafenib.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고형준 | - |
dc.contributor.author | 정은지 | - |
dc.date.accessioned | 2015-04-24T16:42:02Z | - |
dc.date.available | 2015-04-24T16:42:02Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0007-1161 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/104008 | - |
dc.description.abstract | BACKGROUND: To investigate the effect of orally administered sorafenib, a multikinase inhibitor, in a mouse model of choroidal neovascularisation (CNV). METHODS: Sorafenib or vehicle was administered orally to female C57BL/6 mice at the onset (day 0) of experiments. CNV was induced by laser photocoagulation the following day. After 14 days, mice were perfused with fluorescein-labelled dextran, and the area of CNV was measured on choroidal flat mounts by image analysis. In some groups of mice, treatments were started 7 days after the laser photocoagulation to determine the effect of the agent on established CNV. Expression of phosphorylated extracellular signal-regulated kinase (p-ERK) in choroidal tissues was measured by Western blot analysis to demonstrate the kinase-inhibitory effect of sorafenib in intracellular signalling pathways involved in CNV formation. RESULTS: Sorafenib significantly reduced the extent of CNV in a dose-dependent manner. The area of CNV was reduced by 43% in the 30 mg/kg/day group and by 61% in the 60 mg/kg/day group compared with vehicle-treated controls (both p<0.0001). Oral administration of sorafenib also caused significant regression of established CNV. The area of CNV was reduced by 59% in the 30 mg/kg/day group and by 66% in the 60 mg/kg/day group compared with both baseline and control measurements (p<0.0001). The expression of p-ERK in choroidal tissues was increased within 1 day of laser photocoagulation and remained elevated for 2 weeks. The expression of p-ERK was suppressed by sorafenib. CONCLUSIONS: Sorafenib demonstrated antiangiogenic properties in a mouse model of CNV and may be useful in the treatment of CNV | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | BRITISH JOURNAL OF OPHTHALMOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Administration, Oral | - |
dc.subject.MESH | Angiogenesis Inhibitors/administration & dosage* | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Benzenesulfonates/administration & dosage* | - |
dc.subject.MESH | Blotting, Western | - |
dc.subject.MESH | Choroidal Neovascularization/drug therapy* | - |
dc.subject.MESH | Dextrans/administration & dosage | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluoresceins/administration & dosage | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Mice, Inbred C57BL | - |
dc.subject.MESH | Niacinamide/analogs & derivatives | - |
dc.subject.MESH | Phenylurea Compounds | - |
dc.subject.MESH | Pyridines/administration & dosage* | - |
dc.title | Inhibition of choroidal neovascularisation in mice by systemic administration of the multikinase inhibitor, sorafenib. | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Ophthalmology (안과학) | - |
dc.contributor.googleauthor | E J Chung | - |
dc.contributor.googleauthor | S Yoo | - |
dc.contributor.googleauthor | H J Lim | - |
dc.contributor.googleauthor | S H Byeon | - |
dc.contributor.googleauthor | J H Lee | - |
dc.contributor.googleauthor | H J Koh | - |
dc.identifier.doi | 10.1136/bjo.2008.149187 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00152 | - |
dc.contributor.localId | A03180 | - |
dc.contributor.localId | A03689 | - |
dc.relation.journalcode | J00412 | - |
dc.identifier.eissn | 1468-2079 | - |
dc.identifier.pmid | 19028740 | - |
dc.identifier.url | http://bjo.bmj.com/content/93/7/958.long | - |
dc.contributor.alternativeName | Koh, Hyoung Jun | - |
dc.contributor.alternativeName | Chung, Eun Jee | - |
dc.contributor.affiliatedAuthor | Koh, Hyoung Jun | - |
dc.contributor.affiliatedAuthor | Chung, Eun Jee | - |
dc.citation.volume | 93 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 958 | - |
dc.citation.endPage | 963 | - |
dc.identifier.bibliographicCitation | BRITISH JOURNAL OF OPHTHALMOLOGY, Vol.93(7) : 958-963, 2009 | - |
dc.identifier.rimsid | 46764 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.